Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosbretabulin - Oncotelic Therapeutics

Next Previous
X
Search
Drug Profile

Fosbretabulin - Oncotelic Therapeutics

Alternative Names: CA4DP; CA4P; Combretastatin A-4 phosphate - Oncotelic Therapeutics; Combretastatin A4 prodrug; Combretastatin-A4; Combretastatin-A4 phosphate; CRC 87-09; CRC-98-09; CS-A4; Fosbretabulin disodium; Fosbretabulin tromethamine; NSC-613729; Zybrestat®

Latest Information Update: 03 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; National Cancer Institute (USA); Oncotelic Therapeutics; OXiGENE; University of Aarhus; University of Florida; University of Kentucky
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Combretastatins; Eye disorder therapies; Small molecules; Stilbenes
  • Mechanism of Action Cadherin 5 inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Neuroendocrine tumours; Thyroid cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Malignant melanoma
  • No development reported Cancer
  • Discontinued Age-related macular degeneration; Colorectal cancer; Diabetic retinopathy; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Leukaemia; Malignant carcinoid syndrome; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Polypoidal choroidal vasculopathy; Psoriasis; Rheumatoid arthritis; Thyroid cancer

Most Recent Events

  • 31 Dec 2023 Clinical trials in Malignant melanoma (Combination therapy, In adults, In children) (IV) prior to December 2023
  • 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Combination therapy, Second-line therapy or greater) in Unknown (IV)
  • 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Monotherapy, Second-line therapy or greater) in Unknown (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top